Your browser doesn't support javascript.
loading
A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus.
Werth, V P; Merrill, J T.
Affiliation
  • Werth VP; Corporal Michael J. Crescenz VAMC, Philadelphia, PA, U.S.A.
  • Merrill JT; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, PA, U.S.A.
Br J Dermatol ; 180(5): 964-965, 2019 05.
Article in En | MEDLINE | ID: mdl-31025748
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azetidines / Lupus Erythematosus, Cutaneous / Lupus Erythematosus, Systemic Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Dermatol Year: 2019 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Azetidines / Lupus Erythematosus, Cutaneous / Lupus Erythematosus, Systemic Type of study: Clinical_trials Limits: Humans Language: En Journal: Br J Dermatol Year: 2019 Document type: Article Affiliation country: Estados Unidos Country of publication: Reino Unido